Liver cancer surgery Follow-Up: could a targeted chemo shot keep cancer away?
NCT ID NCT07417397
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether giving a targeted chemotherapy treatment (TACE) after liver cancer surgery can prevent the cancer from coming back. It involves 442 patients with high-risk features for recurrence. Half will receive TACE, and the other half will have intensive monitoring only, with researchers comparing how long each group stays cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lobaplatin and ethiodized poppyseed oil (chemotherapy) delivered via transarterial chemoembolization (TACE)
- What this could lead to
- If successful, this could provide a standard way to lower the chance of liver cancer returning after surgery, improving long-term survival.
- What could go wrong
- This is a large Phase 3 trial, but previous studies have disagreed on whether adjuvant TACE helps. The procedure also carries risks like liver damage or side effects from chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADJUVANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Guangxi Medical University Cancer Hospital
RECRUITINGNanning, 530021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer vaccine prime the body to better fight liver tumors?
- Training the immune system to hunt down leftover liver cancer cells
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Could a genetic marker guide future cancer therapies in taiwan?
- Can a tumor-zapping procedure also wake up the immune system?
- A machine that keeps donor livers alive outside the body — could it transform transplantation?